Latest period
$137.00M
YoY change
-81.7%
5Y CAGR
+23.3%
Peak year (2024)
$1.05B
Cumulative CapEx
$2.99B
CapEx history chart for Moderna (MRNA) from 2016 to 2025
Latest: $192.00M
CapEx growth chart for Moderna (MRNA) from 2016 to 2025
Latest: -81.7%
CapEx history table for Moderna (MRNA) from 2016 to 2025
| 2025 | $192.00M | -81.7% | −$859.00M | ||
| 2024 | $1.05B | +48.7% | +$344.00M | ||
| 2023 | $707.00M | +76.8% | +$307.00M | ||
| 2022 | $400.00M | +40.8% | +$116.00M | ||
| 2021 | $284.00M | +321.1% | +$216.55M | ||
| 2020 | $67.45M | +113.8% | +$35.89M | ||
| 2019 | $31.55M | -70.2% | −$74.21M | ||
| 2018 | $105.77M | +81.1% | +$47.37M | ||
| 2017 | $58.40M | +76.2% | +$25.26M | ||
| 2016 | $33.14M | — | — |
- 2025$192.00M-81.7%
- 2024$1.05B+48.7%
- 2023$707.00M+76.8%
- 2022$400.00M+40.8%
- 2021$284.00M+321.1%
- 2020$67.45M+113.8%
- 2019$31.55M-70.2%
- 2018$105.77M+81.1%
- 2017$58.40M+76.2%
- 2016$33.14M—
CapEx values are taken from Moderna's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Moderna (MRNA)
According to Moderna's latest reported financial statements, the company's current CapEx (TTM) is $137.00M. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Moderna (MRNA) CapEx totalled $192.00M – plunged 81.7% year-over-year.
Moderna CapEx has grown on net over the period, with a +23.3% compound annual growth rate over 2020–2025 (5 years).
Moderna CapEx peaked at $1.05B in 2024; the latest annual figure is $192.00M in 2025 (81.7% below peak).
Across the available history, CapEx reached its high of $1.05B in 2024 and its low of $31.55M in 2019.
Moderna Capital Expenditures by Year
Moderna Capital Expenditures 2025: $192.00M
Moderna CapEx in 2025 was $192.00M, plunged 81.7% below 2024.
Moderna Capital Expenditures 2024: $1.05B
2024's CapEx for Moderna came in at $1.05B, surged 48.7% from 2023. This figure represents the highest annual value in the available history.
Moderna Capital Expenditures 2023: $707.00M
Moderna posted CapEx of $707.00M in 2023, surged 76.8% from 2022.
Moderna Capital Expenditures 2022: $400.00M
In 2022, Moderna reported CapEx of $400.00M, surged 40.8% from 2021.
Moderna Capital Expenditures 2021: $284.00M
Moderna CapEx in 2021 was $284.00M.
See more financial history for Moderna (MRNA).
Sector peers by CapEx
Healthcare peers of Moderna (MRNA), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Moderna (MRNA) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation